NeuPath Health Valuation
| NPTH Stock | CAD 0.37 0.01 2.78% |
NeuPath Health seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of NeuPath Health from analyzing the firm fundamentals such as Profit Margin of (0.01) %, return on equity of -0.0224, and Current Valuation of 29.39 M as well as examining its technical indicators and probability of bankruptcy.
Price Book 0.9807 | Enterprise Value 29.4 M | Enterprise Value Ebitda 9.2793 | Price Sales 0.2602 | Forward PE 27.4725 |
Overvalued
Today
Please note that NeuPath Health's price fluctuation is out of control at this time. Calculation of the real value of NeuPath Health is based on 3 months time horizon. Increasing NeuPath Health's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NeuPath stock is determined by what a typical buyer is willing to pay for full or partial control of NeuPath Health. Since NeuPath Health is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NeuPath Stock. However, NeuPath Health's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.37 | Real 0.3 | Hype 0.36 |
The intrinsic value of NeuPath Health's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NeuPath Health's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NeuPath Health helps investors to forecast how NeuPath stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NeuPath Health more accurately as focusing exclusively on NeuPath Health's fundamentals will not take into account other important factors: NeuPath Health Cash |
|
NeuPath Health Total Value Analysis
NeuPath Health is now anticipated to have takeover price of 29.39 M with market capitalization of 20.66 M, debt of 5.76 M, and cash on hands of 7.48 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the NeuPath Health fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
29.39 M | 20.66 M | 5.76 M | 7.48 M |
NeuPath Health Investor Information
About 18.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.98. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NeuPath Health recorded a loss per share of 0.01. The entity last dividend was issued on the 6th of July 2020. NeuPath Health is performing exceptionally good at this time. It has a great probability to report excellent financial results in December.NeuPath Health Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NeuPath Health has an asset utilization ratio of 176.28 percent. This indicates that the Company is making C$1.76 for each dollar of assets. An increasing asset utilization means that NeuPath Health is more efficient with each dollar of assets it utilizes for everyday operations.NeuPath Health Ownership Allocation
NeuPath Health maintains a total of 56.6 Million outstanding shares. Roughly 80.61 % of NeuPath Health outstanding shares are held by general public with 1.68 pct. owned by insiders and only 17.71 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NeuPath Health Profitability Analysis
The company reported the revenue of 72.81 M. Net Loss for the year was (728 K) with profit before overhead, payroll, taxes, and interest of 15.16 M.About NeuPath Health Valuation
Our relative valuation model uses a comparative analysis of NeuPath Health. We calculate exposure to NeuPath Health's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NeuPath Health's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 13.9 M | 12.4 M |
Additional Tools for NeuPath Stock Analysis
When running NeuPath Health's price analysis, check to measure NeuPath Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuPath Health is operating at the current time. Most of NeuPath Health's value examination focuses on studying past and present price action to predict the probability of NeuPath Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuPath Health's price. Additionally, you may evaluate how the addition of NeuPath Health to your portfolios can decrease your overall portfolio volatility.